Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome

Atopic Dermatitis Clinical Trial

Official title:

A Multicenter, Randomized, Double-blind, Vehicle Controlled, Parallel-group Comparison Trial to Demonstrate the Superiority of 1% OPA-15406 Ointment to the Vehicle in Adult Patients With Atopic Dermatitis (Phase 3 Trial)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03908970
• Other study ID #: 271-102-00007
• Status: Completed
• Phase: Phase 3
• Start date: March 25, 2019
• Est. completion date: December 28, 2019

Study information

• Verified date: January 2021
• Source: Otsuka Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To demonstrate the superiority of IMP (1% OPA-15406 ointment or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in adult patients with AD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 364
• Est. completion date: December 28, 2019
• Est. primary completion date: December 28, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 15 Years to 70 Years

Eligibility

Inclusion Criteria:

• Diagnosis of AD based on the Japanese Dermatological Association's criteria

• History of AD for at least 3 years

• Atopic dermatitis affecting more than or equal to 5%, to less than or equal to 40% of body surface area (BSA, excluding scalp) at the screening and baseline examinations

• IGA score of 2 or 3 at the screening and baseline examinations

Exclusion Criteria:

• Subjects who have an AD or contact dermatitis flare-up defined as a rapid intensification of AD, within 28 days prior to the baseline examination

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• 1% OPA-15406
Twice daily
• Placebos
Twice daily

Locations

Country	Name	City	State
Japan	Kitago Hifuka Clinic	Sapporo

Sponsors (1)

Lead Sponsor	Collaborator
Otsuka Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity	The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 4. Incidence of success in IGA is defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.	At Week 4
Secondary	Change From Baseline in Eczema Area and Severity Index (EASI) Score	The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD, and a negative change from the baseline means improvement and a positive change means worsening. The investigator or sub investigator scored the severity (0-3 points) and affected BSA (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs).	Baseline, Week 4
Secondary	Change From Baseline in Verbal Rating Scale (VRS) for Pruritus Score	The investigator or subinvestigator evaluated the pruritus intensity based on VRS. The subjects evaluated the pruritus intensity according to the following criteria. The subjects recorded the level of pruritus and the time and date of evaluation in a pruritus diary.; 0: None; Mild; Moderate; Severe	Baseline, Week 4